Charles River Laboratories International (CRL) is experiencing near-term pressure on revenue growth as biotech firms scale back on research and development expenditures. The trend, affecting the broader healthcare and life sciences sector, is reflected in declining service demand and margin compression for CRL and its peers.
- CRL reported a 7.3% YoY revenue decline in Q4 2025 due to reduced biotech R&D outsourcing.
- Biotech IPOs fell 42% YoY in 2025, with VC funding down 31%.
- CRL’s new preclinical study contracts dropped 22%, especially in oncology and rare disease areas.
- XLV declined 5.1% in March 2026, underperforming SPY by 2.3 percentage points.
- CRL’s share price fell 14% from January to March 2026.
- CRL is shifting focus to gene editing and AI-driven drug discovery to offset macro pressures.
Charles River Laboratories International (CRL) is confronting a shift in biopharmaceutical investment patterns, with a measurable deceleration in R&D spending across the biotech industry. In the fourth quarter of 2025, CRL reported a 7.3% year-over-year decline in service revenue, attributed to delayed project initiations and reduced outsourcing volumes from mid-cap biotech clients. This marks the first quarterly revenue drop in three years and signals a broader trend as companies prioritize operational efficiency over aggressive innovation pipelines. The slowdown is amplified by macroeconomic pressures, including rising interest rates and tighter capital markets, which have constrained biotech fundraising. Data from publicly available filings show that biotech initial public offerings (IPOs) declined by 42% year-over-year in 2025, with venture capital funding down 31% compared to 2024. These conditions have led to a 22% reduction in new preclinical study contracts for CRL, particularly in oncology and rare disease programs, which historically accounted for over 60% of its service volume. The impact extends beyond CRL. The XLV Health Care Select Sector SPDR Fund, which includes CRL and other major healthcare providers, saw a 5.1% decline in March 2026, underperforming the broader SPY S&P 500 ETF by 2.3 percentage points. Analysts note that investor sentiment has shifted toward defensive healthcare stocks, with a growing emphasis on profitability over growth for biotech service providers. This repricing has led to a 14% drop in CRL’s share price since January 2026, despite consistent cash flow generation. Market participants are now closely monitoring the pace of biotech R&D recovery, with expectations for stabilization not before late 2026. For CRL, the near-term focus remains on cost optimization and expanding into niche therapeutic areas such as gene editing and AI-driven drug discovery, where demand remains resilient.